Tag: Seelos Therapeutics Inc. (NASDAQ: SEEL)


Seelos Therapeutics Inc. (NASDAQ: SEEL) Release Encouraging SLS-004 Study Results Showing SNCA mRNA Downregulation

Seelos Therapeutics Inc. (NASDAQ: SEEL) has announced encouraging in vivo data showing SNCA mRNA and protein expression down-regulation a study evaluating SLS-004 in in-vivo animal models using CRISPR-dCas9 gene therapy tech.Data showed that a single SLS-004 dose resulted in therapeutically desirable SNCA mRNA reduction by 27% and around 40% SNCA […]


Seelos Therapeutics, Inc. (NASDAQ: SEEL) Announces the Dosing of First Patient in Part 2 of a Registrational Study of SLS-002

ACCORDING TO DATA, the US government has been spending more than $70 billion on suicides and suicide attempts, according to data from the Centers for Disease Control and Prevention (CDC). Additionally, a suicidal patient has to wait for an average of 10 days before hospitalization due to the current shortage […]